Tepotinib in second line NSCLC treatment
20 Jan 2026
Dr Coukos talks to ecancertv at WIN 2014 about his work looking at immune cells and tumour environment in ovarian cancer.
Tepotinib in second line NSCLC treatment
The added value of integrative medicine
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Choosing Wisely in endometrial & cervix cancers: Medical therapy
ESMO 2024: Optimising the personalisation of prostate cancer treatment
ASCO 2024: Lung cancer highlights
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for metastatic cervical cancer